NCT07486219

Brief Summary

Lung neoplasms are characterized by a complex interaction between tumor cells and a variety of resident and infiltrating host elements, secreted factors, and extracellular matrix proteins, collectively referred to as the microenvironment. Nowadays, in the setting of lung cancer, and in particular non-small cell lung cancer (NSCLC), the evaluation of microenvironment characteristics can only be performed by a pathologist and only on histological material. By combining different MRI parameters, it may be possible to create a specific imaging "signature" for the three different immune phenotypes and thus be able to make a distinction based on MRI examination.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2020

Completed
6.2 years until next milestone

First Submitted

Initial submission to the registry

March 11, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 20, 2026

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

March 20, 2026

Status Verified

March 1, 2026

Enrollment Period

6.2 years

First QC Date

March 11, 2026

Last Update Submit

March 18, 2026

Conditions

Lung Cancer (NSCLC)

Outcome Measures

Primary Outcomes (1)

  • assessment of the ability of advanced magnetic resonance imaging techniques to distinguish between immune phenotypes in NSCLC.

    up to 36 months

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

will be selected by the multidisciplinary thoracic neoplasms group (GINT) Patients with primary lung cancer

You may qualify if:

  • Primary NSCLC of the lung (TNM 8th edition T parameter ≥T1c)
  • Biopsy examination of the primary tumor adequate at least for PDL-1 quantification
  • Staging CT scan with uncertain N parameter and definite M parameter.

You may not qualify if:

  • Absolute contraindications to magnetic resonance imaging or the administration of gadolinium-based contrast agents

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, 27100, Italy

RECRUITING

MeSH Terms

Conditions

Lung NeoplasmsCarcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Central Study Contacts

Chandra Bortolotto

CONTACT

+390382503761c.bortolotto@smatteo.pv.it

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof

Study Record Dates

First Submitted

March 11, 2026

First Posted

March 20, 2026

Study Start

January 15, 2020

Primary Completion

April 1, 2026

Study Completion

April 1, 2026

Last Updated

March 20, 2026

Record last verified: 2026-03

Locations

IT(1)